Clinical Predictive Value of Serum Angiogenic Factor in Patients with Osteosarcoma |
Chen, Zhe
(Department of Orthopaedics, The Second Affiliated Hospital, Medical College, Zhejiang University)
Chen, Qi-Xin (Department of Orthopaedics, The Second Affiliated Hospital, Medical College, Zhejiang University) Hou, Zhao-Yang (Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University) Hu, Jiong (Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University) Cao, Yan-Guang (Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University) |
1 | Balu S, Pirtea L, Gaje P, et al (2012). The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer. Rom J Morphol Embryol, 53, 479-83. |
2 | Dirkx AE, oude Egbrink MG, Castermans K, et al (2006). Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J, 20, 621-30. DOI |
3 | Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80. |
4 | Hlobilkova A, Ehrmann J, Knizetova P, et al (2009). Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma, 56, 284-90. DOI |
5 | Kasuya K, Nagakawa Y, Suzuki M, et al (2011). Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Exp Ther Med, 2, 1047-52. |
6 | Kim HS, Lim SJ, Park YK (2009). Anti-angiogenic factor endostatin in osteosarcoma. APMIS, 117, 716-23. DOI |
7 | Lee JA, Ko Y, Kim DH, et al (2012). Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? Cancer Res Treat, 44, 202-9. DOI |
8 | Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8. |
9 | Li CG, Huang XE, Li Y, et al (2011). Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pacific J Cancer Prev, 12, 487-90. |
10 | Limmahakhun S, Pothacharoen P, Theera-Umpon N, et al(2011). Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev, 12, 1717-22. |
11 | Malamitsi-Puchner A, Boutsikou T, Economou E, et al (2005). The role of the anti-angiogenic factor endostatin in intrauterine growth restriction. J Soc Gynecol Investig, 12, 195-7. DOI |
12 | Nataraj NB, Salimath BP (2012). Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma. Cell Signal, 25, 277-94. |
13 | Oda Y, Yamamoto H, Tamiya S, et al (2006). CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol, 19, 738-45. DOI |
14 | Sunshine SB, Dallabrida SM, Durand E, et al (2012). Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A, 109, 11306-11. DOI |
15 | Tan H, Mu G, Zhu W, et al (2011). Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug. Biol Pharm Bull, 34, 545. DOI |
16 |
Tsubaki M, Yamazoe Y, Yanae M, et al (2011). Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF- |
17 | Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6. |
18 | Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90. |
19 | Yang J, McNeish B, Butterfield C, et al (2012). Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J, Epub ahead of print. |
20 | Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4. |
21 | Zhang G, Li M, Jin J, Bai Y (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80. |
22 | Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5. |
23 | Zheng MJ (2009). Endostatin derivative angiogenesis inhibitors. Chin Med J, 122, 1947-51. |
![]() |